e2086
Small moleculeexperimental
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Feb 20, 2023 (NCT05745207)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Orexin receptorANTAGONIST
Orexin receptor antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07308236 | Phase 1 | Dec 31, 2025 | Eisai |
| NCT06481488 | Phase 1 | Jun 25, 2024 | Eisai |
| NCT06462404 | Phase 1 | Jun 20, 2024 | Eisai |
| NCT05745207 | Phase 1 | Feb 20, 2023 | Eisai |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Eisai | For profit | 4 | 4 | 1 | 2023 |
1 organizations
Page 1 / 1